title: Killed Mycobacterium vaccae suspension in children with moderate-to-severe atopic dermatitis: a randomized, double-blind, placebo-controlled trial.
abstract: BACKGROUND
  The hygiene hypothesis is often proposed to explain the high prevalence of atopy in the western world. Dysregulation of the immune system may result from inadequate exposure to micro-organisms such as mycobacteria. A small trial suggested that a killed extract of Mycobacterium vaccae ameliorates atopic dermatitis (AD).
  
  
  OBJECTIVE
  To confirm in a large clinical trial whether killed M. vaccae ameliorates AD in 5-16-year-old children.
  
  
  METHODS
  This was a randomized, placebo-controlled, double-blind, multi-centre study of the effect of intradermal injection of killed M. vaccae (0.1 or 1 mg) on patients, aged 5-16, with moderate-to-severe AD. Patients were followed up for 24 weeks. The primary end point was the change in severity of AD at 12 weeks, assessed using the six area, six-sign, atopic dermatitis (SASSAD) score. Secondary end points included changes in disease extent, patient's global assessment and children's dermatology life quality index.
  
  
  RESULTS
  There were 166 patients randomized. The mean SASSAD score fell to a similar degree at week 12 in all treatment arms: from 33 to 24, (26%) in the high-dose group, from 30 to 23 (25%) in the low-dose group and from 36 to 27 (24%) in the placebo group (P>0.05). Secondary end points followed the same trend. Adverse events were generally those expected to occur in this population. Injection site reactions occurred in 32 patients at week 4.
  
  
  CONCLUSIONS
  M. vaccae was no more effective than the placebo in ameliorating the severity of AD.
authors.affiliation: Department of Dermatology, George Eliot Hospital, Nuneaton, UK. johnberthjones@aol.com
authors.forename: J
authors.initials: J
authors.lastname: Berth-Jones
authors.forename: P D
authors.initials: PD
authors.lastname: Arkwright
authors.forename: D
authors.initials: D
authors.lastname: Marasovic
authors.forename: N
authors.initials: N
authors.lastname: Savani
authors.forename: C R
authors.initials: CR
authors.lastname: Aldridge
authors.forename: S N
authors.initials: SN
authors.lastname: Leech
authors.forename: C
authors.initials: C
authors.lastname: Morgan
authors.forename: S M
authors.initials: SM
authors.lastname: Clark
authors.forename: S
authors.initials: S
authors.lastname: Ogilvie
authors.forename: S
authors.initials: S
authors.lastname: Chopra
authors.forename: J I
authors.initials: JI
authors.lastname: Harper
authors.forename: C H
authors.initials: CH
authors.lastname: Smith
authors.forename: G A W
authors.initials: GA
authors.lastname: Rook
authors.forename: P S
authors.initials: PS
authors.lastname: Friedmann
mesh_terms: D000293:Adolescent; D001428:Bacterial Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*; D002648:Child; D002675:Child, Preschool; D003876:Dermatitis, Atopic / Q000276:immunology* / Q000628:therapy; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004485:Eczema / Q000188:drug therapy / Q000276:immunology; D005260:Female; D006801:Humans; D007271:Injections, Intradermal / Q000009:adverse effects; D008297:Male; D009161:Mycobacterium / Q000276:immunology*; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D001428:Bacterial Vaccines; C451081:SRL172